Complete Bibilography

Visit PubMed to view Dr. Seth Pollack's complete publication record,

Selected Publications

Zhang S, Kholi K, Yao L, Black RG, Spadinger S, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee B, Pierce R, Riddell SR, Jones RL, Pollack SM. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019 Jun 6. doi: 10.1158/2326-6066.CIR-18-0940.  

Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen J, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SMFirst-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 Jun 21.

Pollack SM, He Q, Yearley JH, Emerson R, Vignalli M, Zhang Y, Redman MW, Baker KK, Cooper S,  Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL. T Cell Infiltration and Clonality Correlate with PD-1 and PD-L1 Expression in Soft Tissue Sarcomas. Cancer. 2017; 123(17):3291-3304.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU 3rd, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014 Oct 14;2(1):36